当前位置: 首页 >> 检索结果
1. Impact of Initial Extensive Ablation on Left Atrial Gaps During Redo Procedures and Subsequent Outcomes in Persistent Atrial Fibrillation.
作者: Masato Okada.;Koichi Inoue.;Nobuaki Tanaka.;Masaharu Masuda.;Tetsuya Watanabe.;Nobuhiko Makino.;Yasuyuki Egami.;Takafumi Oka.;Hitoshi Minamiguchi.;Miwa Miyoshi.;Takashi Kanda.;Yasuhiro Matsuda.;Masato Kawasaki.;Koji Tanaka.;Yuko Hirao.;Shungo Hikoso.;Akihiro Sunaga.;Tomoharu Dohi.;Daisaku Nakatani.;Katsuki Okada.;Yohei Sotomi.;Yasushi Sakata.; .
来源: Circ Arrhythm Electrophysiol. 2025年18卷6期e013612页
The efficacy of extensive linear ablation strategies, in addition to pulmonary vein (PV) isolation, remains controversial in persistent atrial fibrillation (AF) ablation. Gaps in previously ablated lesions can induce arrhythmias and potentially decrease the effectiveness of extensive ablation. This study evaluated the incidence of conduction gaps, gap-related reentry, and subsequent recurrence following redo AF ablation in the EARNEST-PVI trial (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation; REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03514693).
2. Marshall-Plan Ablation Strategy Versus Pulmonary Vein Isolation in Persistent AF: A Randomized Controlled Trial.
作者: Nicolas Derval.;Romain Tixier.;Josselin Duchateau.;Xavier Bouteiller.;Timothé Loock.;Arnaud Denis.;Rémi Chauvel.;Benjamin Bouyer.;Marine Arnaud.;Masaaki Yokoyama.;Christopher Kowalewski.;Cinzia Monaco.;Ciro Ascione.;Frédéric Sacher.;Mélèze Hocini.;Pierre Jaïs.;Michel Haïssaguerre.;Thomas Pambrun.
来源: Circ Arrhythm Electrophysiol. 2025年18卷5期e013427页
Beyond pulmonary vein (PV) isolation, the optimal ablation strategy for persistent atrial fibrillation (AF) remains poorly defined. The purpose of this study was to compare 2 ablation strategies in the treatment of patients with persistent AF: a comprehensive ablation strategy based on anatomic considerations versus PV isolation alone.
3. 10-Year Outcomes of Deferred or Conventional Stent Implantation in Patients With STEMI (DANAMI-3-DEFER).
作者: Jasmine Melissa Marquard.;Thomas Engstrøm.;Henning Kelbæk.;Rasmus Paulin Beske.;Utsho Islam.;Dan Eik Høfsten.;Lene Holmvang.;Frants Pedersen.;Christian Juhl Terkelsen.;Evald Høj Christiansen.;Hans-Henrik Tilsted.;Charlotte Glinge.;Reza Jabbari.;Ashkan Eftekhari.;Bent Raungaard.;Peter Clemmensen.;Hans Erik Bøtker.;Lisette Okkels Jensen.;Lars Køber.;Jacob Thomsen Lønborg.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015369页
Primary percutaneous coronary intervention (PCI) with stenting is recommended in ST-segment-elevation myocardial infarction. Immediate stenting may cause distal embolization, microvascular damage, and flow disturbances, leading to adverse outcomes. We report the 10-year clinical outcomes of deferred stenting versus conventional PCI in patients with ST-segment-elevation myocardial infarction.
4. Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.
作者: Constantin-Cristian Topriceanu.;Christoffer Rasmus Vissing.;Anna Axelsson Raja.;Sharlene M Day.;Mark W Russell.;Kenneth Zahka.;Alexandre C Pereira.;Steven D Colan.;Anne M Murphy.;Charles Canter.;Richard G Bach.;Matthew T Wheeler.;Joseph W Rossano.;Anjali T Owens.;Luisa Mestroni.;Matthew R G Taylor.;James C Moon.;Gabriella Captur.;Amit R Patel.;Ivan Wilmot.;Jonathan H Soslow.;Jason R Becker.;Christine E Seidman.;Neal K Lakdawala.;Henning Bundgaard.;Usman A Tahir.;Carolyn Y Ho.
来源: Circ Heart Fail. 2025年18卷6期e012393页
In hypertrophic cardiomyopathy (HCM), the mechanisms through which pathogenic sarcomere variants (G+) lead to left ventricular hypertrophy (LVH) are not understood.
5. Novel Contrast-Derived Indices of Coronary Microvascular Function: Potential Clinical and Cost Benefits.
作者: Daniel T Y Ang.;Damien G Collison.;Ross J McGeoch.;David Carrick.;Robert A Sykes.;Conor Bradley.;Anna L Kamdar.;Andy Jong.;Richard A Brogan.;David A MacDougall.;Peter J McCartney.;J Paul Rocchiccioli.;Andrew P Apps.;C Aengus Murphy.;Keith E Robertson.;Aadil Shaukat.;Angie Ghattas.;Francis R Joshi.;Arvind Sood.;Richard I S Good.;Brian O'Rourke.;Hany Eteiba.;M Mitchell Lindsay.;Alex McConnachie.;Colin Berry.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015058页
Intravenous adenosine induces stable myocardial hyperemia for coronary microvascular function testing. Iodinated radiographic contrast media induce transient, submaximal hyperemia. We assessed the feasibility, diagnostic value, and potential cost-effectiveness of contrast-derived indices of microvascular function.
6. Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older Adults.
作者: Michelle A Fravel.;Michael E Ernst.;Robyn L Woods.;Suzanne G Orchard.;Shiva Ganjali.;James B Wetmore.;Christopher Reid.;Joanne Ryan.;Kevan R Polkinghorne.;Rory Wolfe.;Mark R Nelson.;Sophia Zoungas.;Zhen Zhou.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷6期e011719页
The ability of the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator to accurately assign 10-year atherosclerotic cardiovascular disease (ASCVD) risk in older individuals, including those aged ≥80 years, is unknown. This study compares PREVENT with the 2013 Pooled Cohort Equation (PCE) calculator for predicting 10-year ASCVD risk in a large cohort of older adults.
7. Impact of Acute Antioxidant and Tetrahydrobiopterin (BH4) Administration on Locomotor Muscle Microvascular Function in Patients With Heart Failure.
作者: Stephen M Ratchford.;Heather L Clifton.;Jayson R Gifford.;D Taylor LaSalle.;Taylor S Thurston.;Kanokwan Bunsawat.;Jeremy K Alpenglow.;Josephine B Wright.;Markus Amann.;John J Ryan.;D Walter Wray.
来源: Circ Heart Fail. 2025年18卷6期e012446页
Peripheral microvascular dysfunction is a hallmark feature of both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) pathophysiology, due partly to impairments in nitric oxide signaling secondary to tetrahydrobiopterin (BH4) deficiency and oxidative stress.
8. Adenosine Contrast Correlations in Evaluating Revascularization: The (ACCELERATION) Study.
作者: Rajesh V Swaminathan.;Guillaume Marquis-Gravel.;Laurie-Anne Boivin-Proulx.;Daniel K Benjamin.;Aruna Rikhi.;Ganesh Raveendran.;Jeff W Chambers.;Arnold H Seto.;Jayant Bagai.;Roseann White.;Jorge Antonio Gutierrez.;Thomas J Povsic.;Sunil V Rao.;Mitchell W Krucoff.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015240页
Injection of contrast media for rapid measurement of contrast fractional flow reserve (cFFR) obviates the side effects and time requirements of adenosine fractional flow reserve (aFFR) and improves diagnostic performance relative to nonhyperemic pressure ratios. However, studies of cFFR have had variable delivery of contrast. We evaluated the diagnostic performance of cFFR using an automated contrast injector with a standardized volume and rate of delivery of contrast to the reference standard aFFR.
9. Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.
作者: Jesper Kjaergaard.;Christian Holdflod Møller.;Sebastian Wiberg.;Astrid Duus Mikkelsen.;Hasse Møller-Sørensen.;Hanne Berg Ravn.;Jesper Ravn.;Peter Skov Olsen.;Dan E Høfsten.;Søren Boesgaard.;Lars Køber.;Jens Christian Nilsson.;Christian Hassager.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014961页
GLP-1 (glucagon-like peptide-1) agonists have been proven beneficial in reducing the risk of and injury associated with several cardiovascular diseases. The efficacy in cardiopulmonary bypass-assisted cardiac surgery is unknown. This trial aimed to investigate the efficacy of an infusion of the GLP-1 agonist exenatide during and after open-heart surgery in reducing the risk of death and major organ failure.
10. Impact of Calcified Raphe on TAVR in Bicuspid Patients: Predicting Redo-TAVR Feasibility and Virtual Planning Implications.
作者: Pavan Reddy.;Fernando J Rodriguez-Weisson.;Giorgio A Medranda.;Ilan Merdler.;Matteo Cellamare.;Paul Gordon.;Afshin Ehsan.;Puja Parikh.;Thomas Bilfinger.;Maurice Buchbinder.;David Roberts.;Nicholas Hanna.;Itsik Ben-Dor.;Lowell F Satler.;Hector M Garcia-Garcia.;Federico M Asch.;Gaby Weissman.;Anita Sadeghpour.;Christian C Schults.;Ron Waksman.;Toby Rogers.
来源: Circ Cardiovasc Interv. 2025年18卷6期e014802页
Patients with bicuspid aortic stenosis who receive transcatheter aortic valve replacement (TAVR) may require subsequent valve interventions in their lifetime; however, the feasibility of redo-TAVR in this population is uncertain. We aimed to assess redo-TAVR feasibility in bicuspid patients and develop a predictive virtual valve planning algorithm.
11. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
作者: Andre Zimerman.;Ana Laura F Kunzler.;Brittany N Weber.;Xinhui Ran.;Sabina A Murphy.;Huei Wang.;Narimon Honarpour.;Anthony C Keech.;Peter S Sever.;Marc S Sabatine.;Robert P Giugliano.
来源: Circulation. 2025年151卷20期1467-1476页
Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but not hsCRP (high-sensitivity C-reactive protein) levels, and reduced the risk of cardiovascular events.
12. Impact of In-Hospital Quality of Care Improvement Initiative on Secondary Prevention of Acute Coronary Syndrome in Six Months After Patient Discharge: A Large Stepped Wedge- and Cluster-Randomized Controlled Trial.
作者: Gaoqiang Xie.;Anushka Patel.;Xin Du.;Yihong Sun.;Xian Li.;Tao Wu.;Zhixin Hao.;Runlin Gao.;Yangfeng Wu.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011441页
Patients discharged after acute coronary syndrome experience a high risk of major adverse cardiovascular events (MACE) within the first 6 months. We examined whether a quality of care improvement initiative implemented in hospitals affects clinical preventive management and outcomes after discharge.
13. Comparing the Efficacy of Sirolimus and Paclitaxel-Eluting Balloon Catheters in the Treatment of Coronary In-Stent Restenosis: A Prospective Randomized Study (TIS 2 Study).
作者: Leos Pleva.;Pavel Kukla.;Tomas Kovarnik.;Jana Zapletalova.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014677页
Current therapy for in-stent restenosis (ISR) is based on drug-eluting stents (DES) or drug-eluting balloon catheters. This prospective randomized study compared the efficacy of a novel sirolimus-eluting balloon (SEB) catheter to that of a paclitaxel-eluting balloon (PEB) catheter for the treatment of bare-metal stent (BMS-ISR) or DES-ISR.
14. A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
作者: Signe Glargaard.;Jakob Hartvig Thomsen.;Christian Tuxen.;Matias Greve Lindholm.;Christian Axel Bang.;Morten Schou.;Kasper Iversen.;Rasmus Vedby Rasmussen.;Brian Bridal Løgstrup.;Søren Vraa.;Nis Stride.;Ekim Seven.;Anders Barasa.;Marlene Tofterup.;Dan Eik Høfsten.;Kasper Rossing.;Lars Køber.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷16期1150-1161页
TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.
15. Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
作者: Brian R Lindman.;Philippe Pibarot.;Allan Schwartz.;J Bradley Oldemeyer.;Yan Ru Su.;Kashish Goel.;David J Cohen.;William F Fearon.;Vasilis Babaliaros.;David Daniels.;Adnan Chhatriwalla.;Hussam S Suradi.;Pinak Shah.;Molly Szerlip.;Michael J Mack.;Thom Dahle.;William W O'Neill.;Charles J Davidson.;Raj Makkar.;Tej Sheth.;Jeremiah Depta.;James T DeVries.;Jeffrey Southard.;Andrei Pop.;Paul Sorajja.;Rebecca T Hahn.;Yanglu Zhao.;Martin B Leon.;Philippe Généreux.; .
来源: Circulation. 2025年151卷22期1550-1564页
The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance with delayed TAVR in patients with asymptomatic severe aortic stenosis. Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.
16. Short-Term DAPT After Complex PCI With Third-Generation DES: A Post Hoc Analysis of the HOST-IDEA Trial.
作者: Jung-Kyu Han.;Keehwan Lee.;Sang-Hyeon Park.;Seokhun Yang.;Doyeon Hwang.;Jeehoon Kang.;Han-Mo Yang.;Kyung Woo Park.;Hyun-Jae Kang.;Bon-Kwon Koo.;Seung-Ho Hur.;Weon Kim.;Sang-Hyun Park.;Seung Hwan Han.;Sang-Hyun Kim.;Yong Hoon Kim.;Namho Lee.;Seung Jin Lee.;Sanghoon Shin.;Hyo-Soo Kim.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014623页
The optimal duration of dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI) remains unclear. We aim to investigate the efficacy and safety of 3 to 6 months of DAPT over 12 months after complex PCI.
17. Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: A Randomized Clinical Trial.
作者: Varsha Keelara Tanguturi.;Roukoz Abou-Karam.;Fangzhou Cheng.;Rong Duan.;Ignacio Inglessis-Azuaje.;Nathaniel B Langer.;Evin N Yucel.;Jonathan J Passeri.;Judy W Hung.;Sammy Elmariah.
来源: Circulation. 2025年151卷21期1498-1507页
Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. We evaluate the impact of electronic provider notifications (EPNs) on rates of AVR at 1 year.
18. Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial.
作者: Sunil V Rao.;Maria Mori Brooks.;Helen E A D'Agostino.;P Gabriel Steg.;Tabassome Simon.;Herbert D Aronow.;Andrew M Goldsweig.;Shahbaz Malik.;Caroline Alsweiler.;Kalon K L Ho.;Payam Dehghani.;Adriano Caixeta.;Ata R Quraishi.;Simon Robinson.;Jay H Traverse.;Omar Siddiqi.;Dean A Fergusson.;Brian J Potter.;Joshua Schulman-Marcus.;Friederike K Keating.;Jeffrey L Carson.; .
来源: Circ Cardiovasc Interv. 2025年18卷5期e015249页
The MINT trial (Myocardial Ischemia and Transfusion; N=3504) randomized patients with acute myocardial infarction (MI) and hemoglobin ≤10 g/dL to liberal (maintain hemoglobin ≥10 g/dL) or restrictive (maintain hemoglobin ≥8 g/dL) red blood cell transfusion. The results suggested a benefit on 30-day death or MI with a liberal transfusion strategy. The effect of transfusion in patients with acute MI undergoing revascularization is unclear.
19. Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial.
作者: Saibal Kar.;Raj R Makkar.;Brian K Whisenant.;Nadira Hamid.;Hursh Naik.;Peter Tadros.;Matthew J Price.;Gagan Singh.;Jonathan G Schwartz.;Samir Kapadia.;Oluseun Alli.;Samuel Horr.;Puvi Seshiah.;Wayne Batchelor.;Brandon M Jones.;Mustafa I Ahmed.;Raymond Benza.;Ulrich Jorde.;Vinod H Thourani.;Andrew A Ghobrial.;Gilbert H L Tang.;Phillip M Trusty.;Dina Huang.;Rebecca T Hahn.;David H Adams.;Paul Sorajja.; .
来源: Circulation. 2025年151卷23期1630-1638页
One-year outcomes of TRILUMINATE Pivotal (Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid Valve Repair System Pivotal) found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation improved quality of life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization. However, additional follow-up is necessary to determine the prolonged benefits of tricuspid TEER.
20. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
作者: Nikolaus Marx.;John E Deanfield.;Johannes F E Mann.;Rosario Arechavaleta.;Stephen C Bain.;Harpreet S Bajaj.;Katrine Bayer Tanggaard.;Andreas L Birkenfeld.;John B Buse.;Zaklina Davicevic-Elez.;Cyrus Desouza.;Scott S Emerson.;Mads D M Engelmann.;G Kees Hovingh.;Silvio E Inzucchi.;Pardeep S Jhund.;Sharon L Mulvagh.;Rodica Pop-Busui.;Neil R Poulter.;Søren Rasmussen.;Shih-Te Tu.;Darren K McGuire.; .
来源: Circulation. 2025年151卷23期1639-1650页
Both GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter-2) inhibitors (SGLT2i) improve cardiovascular outcomes in people with type 2 diabetes and cardiovascular or chronic kidney disease. However, there are limited data about the effect of combining these agents on cardiovascular and safety outcomes.
|